摘要
视网膜动脉阻塞为眼科急症,临床多采用溶栓治疗,然而溶栓对时间窗有较高要求,考虑到疾病发现不及时等原因,容易错过时间窗。近年来有研究发现,视网膜动脉阻塞的患者肠道菌群结构及数量紊乱,同时在眼科其他疾病中发现肠道菌群可能介导疾病的发生。肠道菌群同样为视网膜动脉阻塞发病的危险因素,其与动脉粥样硬化、高血压等的发生有相关性。在生理结构方面,眼部血管被认为是脑血管在眼部的分支,视网膜中央动脉为眼动脉的分支,故视网膜动脉阻塞也被认为是脑卒中在眼部的表现。在脑卒中的发病中,现认为肠道菌群的作用也不可忽视,近年来有从肠道菌群入手治疗脑卒中。笔者认为可以从调节肠道菌群入手治疗视网膜动脉阻塞。中医药与肠道菌群的关系近年来取得了较大进步,中药对调节肠道菌群具有积极作用。故在治疗视网膜动脉阻塞时,可以应用对调节菌群有益的中药以调节肠道菌群,进而治疗视网膜动脉阻塞。
Retinal artery occlusion is an ophthalmic emergency that is often treated with thrombolysis in clinical practice.However,thrombolysis requires a high time window,and due to reasons such as delayed disease detection,it is easy to miss the time window.In recent years,studies have found that the structure and quantity of gut microbiota in patients with retinal artery occlusion are disrupted.At the same time,in other ophthalmic diseases,it has been found that gut microbiota may mediate the occurrence of diseases.Intestinal flora is also a risk factor for retinal artery occlusion,which is associated with atherosclerosis,hypertension,etc.In terms of physiological structure,ocular blood vessels are considered as branches of cerebral blood vessels in the eye,and the central retinal artery is a branch of the ophthalmic artery.Therefore,retinal artery occlusion is also considered a manifestation of stroke in the eye.In the pathogenesis of stroke,it is now believed that the role of gut microbiota cannot be ignored.In recent years,there have been treatments for stroke that focus on gut microbiota.The author believes that the treatment of retinal artery occlusion can be approached by regulating the gut microbiota.The relationship between traditional Chinese medicine and gut microbiota has made significant progress in recent years,and traditional Chinese medicine has a positive effect on regulating gut microbiota.Therefore,when treating retinal artery occlusion,traditional Chinese medicine that is beneficial for regulating gut microbiota can be applied to regulate gut microbiota,thereby treating retinal artery occlusion.
作者
张懿格
谢立科
郝晓凤
陈子扬
袁航
翟孟凡
鞠品
ZHANG Yige;XIE Like;HAO Xiaofeng;CHEN Ziyang;YUAN Hang;ZHAI Mengfan;JU Pin(The Second Department of Endoscopic Ophthalmology,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)
出处
《中国医药导报》
CAS
2024年第2期45-48,共4页
China Medical Herald
基金
国家自然科学基金面上项目(82174445)
中国中医科学院中央级公益性科研院所基本科研业务“优势病种-医院制剂-新药”研发专项项目(ZZ15-XY-PT-09)。
